INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

	Application Number		09308223	
	Filing Date		1999-08-12	
	First Named Inventor	Georg	g KALLMEYER et al	
	Art Unit		1642	
	Examiner Name	Brand	don J. Fetterolf	
	Attorney Docket Number		2924-139	

				U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines w Relevant Passages or F Figures Appear			
	1	5096885	A	1992-03-17	Pearlman et a					
	2	4597966	A	1986-07-01	Zolton et al					
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.		Add		
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	ner Cite No Publication Number Kind Code¹ Date		Publication Date	Name of Pat of cited Doc	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
If you wis	1 h to a	dd additional U.S. Publ	ished Ap	plication citatio			d button	Add		_
If you wis Examiner Initial*	h to a	dd additional U.S. Publ Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	FOREIGN PAT			e or	Remove Pages,Col	or Relevant	T5
Examiner	n to a	Foreign Document	Countr	FOREIGN PAT	Publication	Name of Patente Applicant of cited	e or	Remove Pages,Col where Rel Passages	evant or Relevant	T .

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		09308223
iling Date		1999-08-12
irst Named Inventor	Georg	KALLMEYER et al
Art Unit		1642
Examiner Name	Brand	on J. Fetterolf
Attorney Docket Number		2924-139

Date Considered

If you wis	h to a	d additional Foreign Patent Document citation information please click the Add button Add				
		NON-PATENT LITERATURE DOCUMENTS Remove				
Examiner Initials*	Cite No					
	1	Hora et al., "Development of a lyophilized formulation of interleukin-2", DEVELOP BIOL STANDARD, Vol 74, pp. 295-306 (Karger, Basel, 1991)				
	2	Rote Liste 1996, Gammonativ, 75 007				
	3	Jabionowska et al., "Prevention of recurrent spontaneous abortion by intravenous immunogiobulin' a double-blind placebo-controlled study", HUMAN REPRODUCTION, vol. 14, no. 3, pp. 838-841, 1999.				
	4	Wang et al., "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers", JOURNAL OF PARENTERAL SCIENCE & TECHNOLOGY, 42, 1988, 84-526.				
	5	Lottspeich et al., 'Bloanalytik, Eisevier Spektrum Akademischer Verlag, 2nd Edition (2006), pg. 250.				
	6					
If you wis	h to a	dd additional non-patent literature document citation information please click the Add button Add				
		FXAMINER SIGNATURE				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a 1 See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reion of the Emperor must precede the serial number of the patent document

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. 5 Applicant is to place a check mark here if English language translation is attached

Examiner Signature